Related Experiment Video
Updated: Apr 21, 2026
Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
Published on: August 29, 2012
"Glowing head" mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in
Chi-Ping Day1, John Carter2, Zoe Weaver Ohler3
1Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Abstract:
Preclinical therapeutic assessment currently relies on the growth response of established human cell lines xenografted into immunocompromised mice, a strategy that is generally not predictive of clinical outcomes. Immunocompetent genetically engineered mouse (GEM)-derived tumor allograft models offer highly tractable preclinical alternatives and facilitate analysis of clinically promising immunomodulatory agents. Imageable reporters are essential for accurately tracking tumor growth and response, particularly for metastases. Unfortunately, reporters such as luciferase and GFP are foreign antigens in immunocompetent mice, potentially hindering tumor growth and confounding therapeutic responses. Here we assessed the value of reporter-tolerized GEMs as allograft recipients by targeting minimal expression of a luciferase-GFP fusion reporter to the anterior pituitary gland (dubbed the "Glowing Head" or GH mouse). The luciferase-GFP reporter expressed in tumor cells induced adverse immune responses in wildtype mouse, but not in GH mouse, as transplantation hosts. The antigenicity of optical reporters resulted in a decrease in both the growth and metastatic potential of the labeled tumor in wildtype mice as compared to the GH mice. Moreover, reporter expression can also alter the tumor response to chemotherapy or targeted therapy in a context-dependent manner. Thus the GH mice and experimental approaches vetted herein provide concept validation and a strategy for effective, reproducible preclinical evaluation of growth and response kinetics for traceable tumors.
Insights
Genetically engineered mouse models with reporter expression in the pituitary gland (Glowing Head mice) overcome immune rejection of labeled tumors. This enables accurate preclinical assessment of tumor growth and therapeutic response in immunocompetent hosts.
Area of Science:
- Oncology
- Immunology
- Preclinical Research
Background:
- Current preclinical cancer models using xenografts in immunocompromised mice lack predictive clinical value.
- Immunocompetent genetically engineered mouse (GEM)-derived tumor allografts are valuable for studying immunomodulatory agents.
- Imageable reporters are crucial for tracking tumor growth and metastasis, but can elicit immune responses in immunocompetent hosts.
Purpose of the Study:
- To evaluate reporter-tolerized GEMs as recipients for allograft transplantation.
- To assess the impact of reporter immunogenicity on tumor growth and metastatic potential.
- To validate a strategy for reproducible preclinical evaluation of traceable tumors.
Main Methods:
- Development of "Glowing Head" (GH) mice with minimal, anterior pituitary-targeted expression of a luciferase-GFP fusion reporter.
- Transplantation of reporter-expressing tumor cells into GH mice and wildtype mice.
- Comparison of tumor growth, metastatic potential, and therapeutic response between GH and wildtype recipients.
Main Results:
- Reporter expression in tumor cells induced adverse immune responses in wildtype mice but not in GH mice.
- Tumor growth and metastatic potential were significantly decreased in wildtype mice compared to GH mice due to reporter antigenicity.
- Reporter expression can context-dependently alter tumor response to chemotherapy and targeted therapy.
Conclusions:
- GH mice serve as effective allograft recipients, mitigating reporter-induced immune responses.
- This strategy enables accurate preclinical evaluation of tumor kinetics and therapeutic efficacy in traceable tumors.
- The validated approach supports reproducible and clinically relevant preclinical cancer research.
